Loss of let-7 binding sites resulting from truncations of the 3 ' untranslated region of HMGA2 mRNA in uterine leiomyomas

Center for Human Genetics, University of Bremen, Leobener Strasse ZHG, 28359 Bremen, Germany.
Cancer genetics and cytogenetics (Impact Factor: 1.93). 01/2010; 196(2):119-23. DOI: 10.1016/j.cancergencyto.2009.09.021
Source: PubMed


A subset of uterine leiomyomas (UL) shows chromosomal rearrangements of the region 12q14 approximately q15, leading to an overexpression of the high-mobility group protein A2 gene (HMGA2). Recent studies identified microRNAs of the let-7 family as post-transcriptional regulators of HMGA2. Intragenic chromosomal breakpoints might cause truncated HMGA2 transcripts lacking part of the 3' UTR. The corresponding loss of let-7 complementary sites (LCS) located in the 3' UTR would therefore stabilize HMGA2 mRNA. The aim of this study was to check UL with rearrangements of the chromosomal region 12q14 approximately 15 for truncated HMGA2 transcripts by real-time reverse-transcription polymerase chain reaction. In 8/13 leiomyomas with aberrations of chromosomal region 12q15, the results showed the presence of the complete 3' UTR with all LCS. A differential expression with highly reduced 3' untranslated region levels was found in 5/13 myomas. In two of these, full-length transcripts were almost undetectable. Truncated transcripts were apparently predominant in roughly one-third of UL with chromosomal rearrangements affecting the HMGA2 locus, where they lead to a higher stability of its transcripts and subsequently contribute to the overexpression of the protein. The assay used is also generally suited to detect submicroscopic alterations leading to truncated transcripts of HMGA2.

Download full-text


Available from: Anke Meyer, Oct 13, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MYB is a leucine zipper transcription factor that is essential for hematopoesis and for renewal of colonic crypts. There is also ample evidence showing that MYB is leukemogenic in several animal species. However, it was not until recently that clear evidence was presented showing that MYB actually is an oncogene rearranged in human cancer. In a recent study, a novel mechanism of activation of MYB involving gene fusion was identified in carcinomas of the breast and head and neck. A t(6;9) translocation was shown to generate fusions between MYB and the transcription factor gene NFIB. The fusions consistently result in loss of the 3'-end of MYB, including several highly conserved target sites for microRNAs that negatively regulate MYB expression. Deletion of these target sites may disrupt the repression of MYB, leading to overexpression of MYB-NFIB transcripts and protein and to transcriptional activation of critical MYB target genes associated with apoptosis, cell cycle control, cell growth/angiogenesis and cell adhesion. This study, together with previous and recent data showing rearrangements and copy number alterations of the MYB locus in T-cell leukemia and certain solid tumors, will be the main focus of this review.
    Full-text · Article · Aug 2010 · Cell cycle (Georgetown, Tex.)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Noncoding RNAs are key players in the regulation of complex cellular processes. Over the years, it has been demonstrated that their abnormal expression is associated with many human pathologies including developmental and neurobehavioral disorders, diabetes, obesity, and cancer. A wide spectrum of activities and a large number of genes that are regulated by RNA-dependent mechanisms makes the ncRNA molecules attractive targets for developing next generation therapeutic agents. This chapter outlines the principles of RNA regulation, the involvement of various RNAs in human diseases, and the strategies of application of ncRNA-targeted therapeutic approaches. KeywordsCancer-Noncoding RNAs-Therapy
    No preview · Chapter · Sep 2010

  • No preview · Article · Sep 2010 · Academic Journal of Second Military Medical University
Show more